Skip to main content
. 2025 Aug 21;12(2):e003490. doi: 10.1136/openhrt-2025-003490

Figure 3. Apolipoprotein B was statistically significantly reduced with PCSK9 targeting therapies when compared with control group (placebo on the background of standard lipid-lowering therapy) (p<0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; MD, mean difference; RCT, randomised controlled trial.

Figure 3